



PRODUCT CATALOG

Advanced Wound Care Portfolio

Personalized wound care solutions for clinical teams, providers, and distribution partners.

AMNIOTIC MEMBRANES

ANTIMICROBIAL MATRICES

AUTOLOGOUS BLOOD-DERIVED

A focused wound-care portfolio

The product information in this catalog has been researched directly from BioLab Holdings' current public website and linked product flyers. Terminology and product positioning are kept close to the manufacturer source.


PRODUCT	CODE	CORE POSITIONING
Membrane Wrap™	Q4205	Dual-layer amniotic membrane
Membrane Wrap - Lite™	Q4373	Single-layer amniotic membrane
Tri-Membrane Wrap™	Q4344	Triple-layer amniotic membrane
Membrane Wrap - Hydro™	Q4290	Hydrated dual-layer amniotic membrane
Membrane Wrap - Amniotic Hydro™	—	Amnion-hydrated dual-layer membrane
Membrane Lite Restore - Ocular™	—	Single-layer ocular amniotic membrane
Microlyte® SAM™	A2005	Synthetic antimicrobial matrix
Microlyte® PainGuard™	A2040	Antimicrobial matrix + lidocaine HCl
APIS®	A2010	Bioengineered wound product

How the portfolio fits together

Protective coverings: BioLab's membrane family provides tissue-derived coverings across chronic wounds and, for the ocular product, ocular surfaces. **Antimicrobial technology:** Microlyte products add a synthetic antimicrobial matrix, with PainGuard adding uniform unit-dose lidocaine HCl. **Bioengineered wound solution:** APIS combines collagen derivative, Manuka honey and hydroxyapatite through its MX® technology.

Amniotic coverings — compare the architecture

BioLab describes these products as human tissue allografts derived from the amniotic membrane that serve as barriers and protective coverings. Each is described as minimally manipulated and compliant with applicable FDA requirements.




Membrane Wrap™ Q4205

Dual-layer amnion-amnion

Barrier and protective covering for wounds.

Product highlights

- Readily available; easy application; 5-year shelf life; FDA compliant.



Membrane Wrap - Lite™ Q4373

Single-layer amnion

Barrier and protective covering for wounds.

Product highlights

- Readily available; easy application; 5-year shelf life; FDA compliant.



Tri-Membrane Wrap™ Q4344

Triple-layer amnion-chorion-amnion

Barrier and protective covering for wounds.

Product highlights

- Readily available; easy application; 5-year shelf life; FDA compliant.



Membrane Wrap - Hydro™ Q4290

Hydrated dual-layer amnion-amnion

Hydrated tissue product providing a barrier and protective covering.

Product highlights

- Readily available; easy application; 5-year shelf life; FDA compliant.

PRODUCT SPECIFICATIONS

Membrane sizing & SKU reference

Use the current BioLab product flyer/order documentation to confirm availability before ordering; BioLab's public materials can change as product assortments are updated.

Membrane Wrap™ • Q4205

SIZE	SKU	WOUND COVERAGE
1×1	MW0101	1 cm ²
2×2	MW0202	4 cm ²
2×3	MW0203	6 cm ²
4×4	MW0404	16 cm ²
4×6	MW0406	24 cm ²
4×8	MW0408	32 cm ²
6×8	MW0608	48 cm ²
10×10	MW1010	100 cm ²

Membrane Wrap - Lite™ • Q4373

SIZE	SKU	WOUND COVERAGE
6×8	ML0608	48 cm ²
8×8	ML0808	64 cm ²
10×10	ML1010	100 cm ²
20×15	ML2015	300 cm ²
20×24	ML2024	480 cm ²

Tri-Membrane & Hydro sizing


Tri-Membrane Wrap™ • Q4344

SIZE	SKU	WOUND COVERAGE
1×1	TM0101	1 cm ²
2×2	TM0202	4 cm ²
2×3	TM0203	6 cm ²
4×4	TM0404	16 cm ²
4×6	TM0406	24 cm ²
4×8	TM0408	32 cm ²
6×8	TM0608	48 cm ²
10×10	TM1010	100 cm ²
20×15	TM2015	300 cm ²
20×24	TM2024	480 cm ²

Membrane Wrap - Hydro™ • Q4290

SIZE	SKU	WOUND COVERAGE
2×2	HM0202	4 cm ²
2×3	HM0203	6 cm ²
4×4	HM0404	16 cm ²
4×6	HM0406	24 cm ²
4×8	HM0408	32 cm ²
6×8	HM0608	48 cm ²
10×10	HM1010	100 cm ²
20×15	HM2015	300 cm ²
20×24	HM2024	480 cm ²

Hydrated and ocular options




Membrane Wrap - Amniotic Hydro™ —

Amnion-hydrated dual-layer amniotic membrane

BioLab describes this product as a dual-layer amnion human tissue allograft hydrated with amniotic fluid. It serves as a barrier and protective covering for wounds and is minimally manipulated.

Product highlights

- Readily available; easy application; 5-year shelf life; FDA compliant.



Membrane Lite Restore - Ocular™ —

Single-layer amniotic allograft membrane

BioLab describes this product for protective covering of the ocular surface. It is a single-layer amnion human tissue allograft, minimally manipulated and derived from amniotic membrane.

Product highlights

- Ocular-surface positioning; terminal sterilization; applicable 21 CFR Part 1271 statement.

Important source distinction

BioLab currently lists both **Membrane Wrap - Amniotic Hydro™** and **Membrane Wrap - Hydro™**. They should not be treated as interchangeable descriptions in the catalog: the former is described as hydrated with amniotic fluid, while the latter is described as a hydrated dual-layer amnion-amnion allograft.

ANTIMICROBIAL TECHNOLOGY

Microlyte® SAM™ • A2005

BioLab describes Microlyte as a fully synthetic antimicrobial matrix containing ionic and metallic silver at low, non-toxic levels.



Microlyte® SAM™ A2005

Synthetic antimicrobial matrix

Designed to conform to wound-bed micro-crevices, maintain a moist healing environment, and sustain consistent reduction of microbial burden.

Product highlights

- 99.99% reduction of a broad range of microbes on the matrix; transparent conformity to wound-bed microtextures; ultra-thin porous bioresorbable polymer matrix; can be used at wound-treatment onset or in surgery.

Current BioLab size/SKU reference

SIZE	SKU	WOUND COVERAGE
16 mm disc	I-ML16DISC	2 cm²
2×2	I-ML0202	4 cm²
3×3	I-ML0303	9 cm²
4×4	I-ML0404	16 cm²
5×5	I-ML0505	25 cm²
6×8	I-ML0608	48 cm²
10×10	I-ML1010	100 cm²

Clinical/technical references are maintained by EmeraNova; efficacy language above includes in-vitro qualifiers where the source uses them.

MicrolYTE® PainGuard™ • A2040

A synthetic antimicrobial matrix combining the MicrolYTE platform with uniform, unit-dose lidocaine HCl release.



MicrolYTE® PainGuard™ A2040

Synthetic antimicrobial matrix with lidocaine HCl

BioLab describes simultaneous antimicrobial activity and pain relief, with the matrix releasing a uniform, unit-dose of lidocaine HCl.

Product highlights

- 99.99% reduction of a broad range of microbes on the matrix; >80% lidocaine HCl release within the first 30 minutes; thin porous resorbable polymer matrix; conforms to wound-bed microtextures.

Current BioLab size / coverage / lidocaine reference

SIZE	SKU	WOUND COVERAGE	LIDOCAINE / PIECE
3×3	I-MLPG0303	9 cm²	3.6 mg
5×5	I-MLPG0505	25 cm²	10 mg
10×10	I-MLPG1010	100 cm²	40 mg

APIS® • A2010

BioLab presents APIS through its partnership with SweetBio as a bioengineered wound product built around MX® technology.



APIS® A2010

Collagen derivative + Manuka honey + hydroxyapatite

The BioLab-linked APIS flyer describes MX® technology as a reconstruction of natural elements into a biomaterial designed around the healing process.

Product highlights

- FDA 510(k) cleared; indicated under healthcare-professional supervision for multiple wound categories; product sizes from 1.6×1.6 cm to 6×8 cm; five billable-size options.

Indications listed in the BioLab-linked APIS flyer

Full- and partial-thickness wounds • pressure ulcers (stages I–IV) • venous stasis ulcers • diabetic ulcers • surface wounds • traumatic wounds healing by secondary intention • surgical wounds • abrasions • donor-site wounds.

Sizing / HCPCS A2010

SIZE	SKU	WOUND COVERAGE
1.6×1.6	APIS-16x16-2	3 cm ²
2.5×2.5	APIS-25x25-2	6 cm ²
4.0×4.0	APIS-40x40-2	16 cm ²
5.0×5.0	APIS-50x50-2	25 cm ²
6.0×8.0	APIS-60x80-2	48 cm ²

Clinical note: the source flyer explicitly states that its testimonial represents one patient's experience and that individual experiences/outcomes may vary.

Science, evidence and quality infrastructure

BioLab's current website emphasizes research, clinical development, regulatory registration and collaboration as part of its wound-care platform.

Research & development	BioLab states that its R&D; team brings scientists, engineers and clinical experts together and integrates biomaterials science with regenerative medicine.
Clinical evidence	BioLab currently highlights clinical data including a chronic diabetic foot-ulcer case involving Membrane Wrap™ and a retrospective analysis of Membrane Wrap Hydro in hard-to-heal wounds.
Clinical trials	BioLab's public news page lists clinical trials involving human placental membrane products and studies evaluating amnion grafts for chronic wounds.
Quality & accreditation	BioLab's current licensing page lists 2026 FDA registration, multiple state/tissue-bank registrations, Canada registration, and AATB accreditation.
Provider & distributor support	BioLab maintains a reimbursement and services function for providers and distributors and describes support around reimbursement and insurance verification.



POINT-OF-CARE AUTOLOGOUS WOUND CARE

FastSkin® Patch

Autologous Whole Blood Clot Technology

FDA 510(k) CLEARED

BK251174 • 11/07/2025

Class II medical device

What it is

The FastSkin® Patch is a self-supporting autologous whole blood clot produced at point-of-care during a wound dressing session. It is intended to support the wound-healing process in chronic and hard-to-heal wounds.

Intended use

The device is intended for safe and rapid preparation of Whole Blood Clots (WBC) from a small sample of the patient's own peripheral blood. Under the supervision of a healthcare professional, the WBC is topically applied for management of exuding cutaneous wounds.

● Example wound types

- Leg ulcers
- Pressure ulcers
- Diabetic ulcers
- Mechanically or surgically debrided wounds

Point-of-care workflow

01

Collect

Small sample of the patient's own peripheral blood.

02

Prepare

FastSkin® Patch prepares the Whole Blood Clot at point of care.

03

Apply

The resulting WBC is topically applied to the exuding wound under professional supervision.

Medicare reimbursement framework

Use as a billing reference only. Coverage and coding must be confirmed with the applicable MAC.

G0465

Diabetic chronic wounds / ulcers

G0460

Non-diabetic chronic wounds / ulcers

- CMS NCD 270.3: national coverage applies to autologous PRP for chronic non-healing diabetic wounds for 20 weeks when the device's FDA-cleared indication includes management of exuding cutaneous wounds.
- Beyond 20 weeks for diabetic wounds, CMS states coverage is determined by the local MAC and the KX modifier is used when applicable.
- Coverage of other chronic non-healing, non-diabetic wounds is determined by the local MAC.



Advancing Wound Care.

Building better access to advanced products.

A focused wound-care portfolio for providers and distribution partners.

GET IN TOUCH

elizabeth@revivamedsolutions.com

REVIVAMED SOLUTIONS

Advanced wound care distribution and provider support